Antengene Corporation Limited (HK:6996) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Antengene Corporation Limited has announced that its drug XPOVIO, used to treat relapsed or refractory diffuse large B-cell lymphoma, will be included in China’s 2024 National Reimbursement Drug List. This inclusion marks a significant milestone for Antengene, potentially enhancing its market presence and financial performance. Investors and shareholders may find this development promising as it could lead to increased adoption and sales of XPOVIO in the region.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.